• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center
ChemPartner Announces Opening of San Francisco Research Facility

ChemPartner Announces Opening of San Francisco Research Facility

Feb 4, 2015 | Press Release |
New facility to help bring CRO to next level of scientific excellence

SHANGHAI – [Feb. 3rd, 2015] –  ChemPartner, a leading science driven, technology based,
high quality preclinical research partner for healthcare companies around the world, recently expanded its global footprint with the establishment of a 24,000 square foot, state-of-the-art research facility in South San Francisco. ChemPartner is the service division of the ShangPharma group.

“We are very excited to announce the opening of ChemPartner’s new state-of-the-art research facility in South San Francisco, one of the global centers of innovation in life science,” said ChemPartner founder and CEO Michael Hui.

“In drug discovery, scientific excellence is the key to success,” Mr.Hui continued.  “By taking the CRO service business to the next level, this new facility will help enable our customers, partners, and business collaborators to interrogate the most complex of drug discovery projects.”

ChemPartner’s new research facility will be staffed by experienced drug research scientists from leading biotechnology companies who will collaborate closely with ChemPartner’s scientists based in China.

“In addition to proximity to the top industry talent, the new facility brings ChemPartner services closer to the biopharmaceutical communities in the US, and will enable us to develop more innovative ways to bring value to our partners.”

The Company noted that the new facility is the first step in a planned build-out of ChemPartner’s research presence in major innovation hubs around the world.

About ChemPartner & ShanghPharma:

The service division of the ShangPharma group, ChemPartner, is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.  The company offers a broad range of high-quality, integrated services across the drug discovery and development process to pharmaceutical and biotechnology companies around the globe. ChemPartner’s services consist of discovery biologics, discovery chemistry, discovery biology and preclinical development, pharmaceutical development, small molecule and biologics manufacturing services.

With the mission of providing and developing cutting edge science and technology to help its partners develop important new therapies, the ShangPharma Group includes divisions wholly focused on enabling new technologies (‘ShangPharma Technologies’) and investing in early stage ideas (‘ShangPharma Investments’) that provide the innovative foundations for future drug therapies.

ShangPharma aims, through all its divisions, to create an ecosystem to allow close interaction between major hospitals and academic centers, by matching them with pharma, biotech, and research institutes it can enable the success of all.  The group is actively investing, licensing, and forming partnerships to better serve the healthcare industry.

Tags: ChemPartnerResearch FacilitySan Francisco
0
Share

You also might be interested in

ChemPartner at CPSA Shanghai 2016

ChemPartner at CPSA Shanghai 2016

Apr 27, 2016

The sixth Clinical & Pharmaceutical Solutions through Analysis (CPSA) was[...]

ChemPartner will be attending World ADC at San Diego USA.

ChemPartner will be attending World ADC at San Diego USA.

Oct 12, 2015

19-22 Oct. 2015, ChemPartner will be attending World ADC at[...]

ChemPartner Receives 2017 Best Life Science CRO Award from GHP

ChemPartner Receives 2017 Best Life Science CRO Award from GHP

Oct 22, 2017

ChemPartner was named Best Life Science CRO in the 2017[...]

Latest News

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities

06/11/2020

Shanghai, China (June 9, 2020) – Shanghai ChemPartner...

ChemPartner Assists the Mount Sinai Health System in Producing Reagent for COVID-19 Research

05/12/2020

Shanghai, China (May 12, 2020) – Shanghai ChemPartner...

ChemPartner and the Gladstone Institutes Announce COVID-19 Research Collaboration

04/17/2020

SAN FRANCISCO, Calif. and SHANGHAI, China. (April 15, 2020)...

ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai

04/02/2020

Shanghai, China (March 17, 2020) – Shanghai ChemPartner...

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

12/18/2019

Shanghai, China (December 17, 2019) – Shanghai ChemPartner...

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

07/19/2019

Contract manufacturers play a significant role when it comes...

Tag Cloud

2017 AACR Agreement Antibody Engineering art Berkeley Lights Best Life Science BIOtech Blend Boston Capital Market Chemistry ChemPartner Congratulates CPhI CPSA Shanghai 2016 CRO DMPK Exploratory Toxicology Labs layout Merger Deal PEGS PEGS CHINA Peptide Pharma Pharmacology product PTF Qidong Quantum Hi-Tech China Biological Research Facility San Diego San Francisco Shanghai Shanghai ChemPartner ShangPharma Sponsor Strategic Corporate Restructuring Tarveda Therapeutic Top 10 CMOs Vice President World ADC

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • Shanghai ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2021 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend
Prev Next